Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward B Garon

Showing results (31-40 of 204) with videos related to

Pageof 21
Sort By:
JTO Clinical and Research Reports|September 30, 2021
The Role of Interleukin 1β in the Pathogenesis of Lung CancerEdward B Garon, James Chih-Hsin Yang, Steven M Dubinett
Clinical Lung Cancer|December 2, 2021
Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized StudiesEdward B Garon, Patrick Peterson, Maria Teresa Rizzo, et al.
Journal of Thoracic Imaging|April 22, 2011
The new staging system for lung cancer: imaging and clinical implicationsSusan M Greaves, Kathleen Brown, Edward B Garon, et al.
Journal of Thoracic Disease|March 30, 2018
High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studiesTim Ellis-Caleo, Aaron Lisberg, D Andrew Tucker, et al.
Psycho-Oncology|August 14, 2012
Uncertainty and psychological adjustment in patients with lung cancerKeiko Kurita, Edward B Garon, Annette L Stanton, et al.
The Oncologist|January 9, 2015
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosisSai-Hong Ignatius Ou, Karen R Sommers, Michele C Azada, et al.
Oncology (Williston Park, N.Y.)|December 10, 2025
Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological CancersAndrea I Nañez Md, Maria A Velez, Mae Zakhour Md, et al.
Lab on a Chip|March 30, 2017
Biophysical isolation and identification of circulating tumor cellsJames Che, Victor Yu, Edward B Garon, et al.
Clinical Lung Cancer|August 3, 2012
A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study designEdward B Garon, Dachuang Cao, Ekaterine Alexandris, et al.
Frontiers in Immunology|July 17, 2020
Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic ReviewPhilippe Rochigneux, Alejandro J Garcia, Brice Chanez, et al.
Pageof 21

Showing results (31-40 of 204) with videos related to

Sort By:
Pageof 21
JTO Clinical and Research Reports|September 30, 2021
The Role of Interleukin 1β in the Pathogenesis of Lung CancerEdward B Garon, James Chih-Hsin Yang, Steven M Dubinett
Clinical Lung Cancer|December 2, 2021
Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized StudiesEdward B Garon, Patrick Peterson, Maria Teresa Rizzo, et al.
Journal of Thoracic Imaging|April 22, 2011
The new staging system for lung cancer: imaging and clinical implicationsSusan M Greaves, Kathleen Brown, Edward B Garon, et al.
Journal of Thoracic Disease|March 30, 2018
High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studiesTim Ellis-Caleo, Aaron Lisberg, D Andrew Tucker, et al.
Psycho-Oncology|August 14, 2012
Uncertainty and psychological adjustment in patients with lung cancerKeiko Kurita, Edward B Garon, Annette L Stanton, et al.
The Oncologist|January 9, 2015
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosisSai-Hong Ignatius Ou, Karen R Sommers, Michele C Azada, et al.
Oncology (Williston Park, N.Y.)|December 10, 2025
Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological CancersAndrea I Nañez Md, Maria A Velez, Mae Zakhour Md, et al.
Lab on a Chip|March 30, 2017
Biophysical isolation and identification of circulating tumor cellsJames Che, Victor Yu, Edward B Garon, et al.
Clinical Lung Cancer|August 3, 2012
A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study designEdward B Garon, Dachuang Cao, Ekaterine Alexandris, et al.
Frontiers in Immunology|July 17, 2020
Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic ReviewPhilippe Rochigneux, Alejandro J Garcia, Brice Chanez, et al.
Pageof 21